• Corey Goodman Corey Goodman, PhD
  • Paul Brooke Paul Brooke
  • Robert Adelman Robert Adelman, MD
  • Behzad Aghazadeh Behzad Aghazadeh, PhD
  • Corey Goodman, PhD

    Dr. Goodman is a scientist, entrepreneur, educator, CEO, and corporate executive. He was formerly President of Pfizer's Biotherapeutics and Bioinnovation Center, and a member of Pfizer's Executive Leadership Team, where he oversaw the discovery and development of biotherapeutics as well as innovative new technologies. Dr. Goodman co-founded Exelixis, Renovis, Second Genome, and Ossianix prior to joining venBio. He was CEO of Renovis as a private and public company, until its acquisition by Evotec A.G. As a result of the acquisition, Dr. Goodman served on the Evotec (XETRA: EVT) Supervisory Board from 2008 until 2009. He is former professor at Stanford University and University of California Berkeley, co-founder of Berkeley's Wills Neuroscience Institute, Investigator with the Howard Hughes Medical Institute, and currently is Adjunct Professor at UC San Francisco. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March of Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics. Among his public policy roles, Dr. Goodman is Chair of the California Council on Science and Technology, advising the Governor and State Legislature, and former Chair of the National Research Council's Board on Life Sciences, advising the Federal Government. Dr. Goodman is currently Chair of the Board of Solstice Biologics, Heart Metabolics, Second Genome, Oligasis, and Ossianix. He is a member of the board of Mirna Therapeutics. Dr. Goodman founded Labrys Biologics, a Fund I investment, with an asset he acquired from Pfizer/Rinat, and was Chair of the Board up until its acquisition by Teva Pharmaceuticals. He co-led Fund I's investments with Dr. Adelman in Solstice Biologics and Heart Metabolics.

  • Paul Brooke

    Mr. Brooke has over 30 years of experience in life science analysis, investing, and management. Mr. Brooke was the Global Head of Health Care Research and Strategy for Morgan Stanley, headed up Morgan Stanley Research and Strategy in the Pacific Basin, and was a Senior Advisor to Morgan Stanley until December 2009. He is a Director of Incyte (NASDAQ: INCY) and a number of private companies. He was Chairman and CEO of Ithaka Acquisition Corp. from 2005 to 2007 and Chairman of Alsius, a successor corporation sold to Zoll in 2009. He was an advisor to MPM Capital and a Member of the Board of Directors of the MPM BioEquities Fund. Mr. Brooke is a Managing Member of PMSV Holdings (an investment advisory firm), and a former Managing Director of Tiger Management. He has served on the Board of Directors of the following publicly listed vehicles: ViroPharma from 2001 to 2014, WebMD from 2000 to 2009, and Cytos Biotechnology from 2012 until 2014.

  • Robert Adelman, MD

    Dr. Adelman has a 30-year history of founding, investing in, and managing companies in the life sciences sector. Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey. Before founding venBio, Dr. Adelman had a seven-year tenure as a Private Equity Partner at OrbiMed Advisors. There he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. Dr. Adelman led Fund I's investments into Aragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Johnson and Johnson. He also led the investment into Seragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Genentech/Roche. Dr. Adelman co-led Fund I's investments with Dr. Goodman into Solstice Biologics and Heart Metabolics and currently serves on the Board of both companies.

  • Behzad Aghazadeh, PhD

    Dr. Aghazadeh has over 16 years of experience in the healthcare sector as an investor, management consultant, and research scientist. Before joining venBio, Dr. Aghazadeh was a Partner with Sio Capital Management and before that, Vice President and Senior Analyst with Bernstein Value Equities. At Bernstein, Dr. Aghazadeh was responsible for global coverage of the healthcare sector for the firm's U.S. and international portfolios comprising $350B in assets under management. Prior to Bernstein, Dr. Aghazadeh was a Principal in the healthcare practice of Booz Allen (now Booz & Co.). During his tenure, Dr. Aghazadeh served corporate executive clients across healthcare verticals and led teams on strategic and operations issues. He also led a program at the US Food and Drug Administration to enhance the productivity of the drug review and approval process. Dr. Aghazadeh was co-lead of Booz Allen's Pharma R&D effectiveness platform. Dr. Aghazadeh has extensive research experience at Memorial Sloan-Kettering Cancer Center and Ludwig-Maximilians University, and has published in leading peer-reviewed journals. Dr. Aghazadeh received a PhD in Biophysics and Biochemistry from Cornell University, and a Masters in Physics from the Ludwig-Maximilians-University in Munich, Germany. He is fluent in English, German and Farsi.